Repligen Corp
NASDAQ:RGEN

Watchlist Manager
Repligen Corp Logo
Repligen Corp
NASDAQ:RGEN
Watchlist
Price: 142.58 USD 0.58% Market Closed
Market Cap: 8B USD
Have any thoughts about
Repligen Corp?
Write Note

Repligen Corp
Other Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Repligen Corp
Other Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Assets CAGR 3Y CAGR 5Y CAGR 10Y
Repligen Corp
NASDAQ:RGEN
Other Assets
$985.6m
CAGR 3-Years
17%
CAGR 5-Years
16%
CAGR 10-Years
53%
Thermo Fisher Scientific Inc
NYSE:TMO
Other Assets
$46.7B
CAGR 3-Years
20%
CAGR 5-Years
13%
CAGR 10-Years
9%
Danaher Corp
NYSE:DHR
Other Assets
$42.2B
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
10%
Mettler-Toledo International Inc
NYSE:MTD
Other Assets
$672.4m
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Other Assets
$4B
CAGR 3-Years
0%
CAGR 5-Years
5%
CAGR 10-Years
3%
IQVIA Holdings Inc
NYSE:IQV
Other Assets
$15.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
41%
No Stocks Found

Repligen Corp
Glance View

Market Cap
8B USD
Industry
Life Sciences Tools & Services

Repligen Corp., a prominent player in the bioprocessing industry, has carved out a niche that centers on providing high-quality bioprocessing solutions for the production of biologics, particularly therapeutic proteins and monoclonal antibodies. Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen has transformed itself from a developer of research tools into a critical partner for biopharmaceutical manufacturers. The company is primarily engaged in producing innovative products that enhance the efficiency and effectiveness of biomanufacturing processes. Its offerings range from filtration systems to cell culture media, all designed to accelerate drug development and ensure consistent product quality. Through strategic acquisitions and partnerships, Repligen has expanded its portfolio and technological capabilities, positioning itself as a leading provider in a high-demand market driven by the growing need for biologic therapies. For investors, Repligen represents a compelling opportunity rooted in its impressive growth trajectory and strong financial performance. The company has consistently reported rising revenues, bolstered by the increasing global demand for biologics and bioprocessing innovations. Repligen’s continuous investment in research and development ensures that it remains at the forefront of technological advancements, while its robust customer base includes some of the world’s leading pharmaceutical and biotech companies. With a strong balance sheet and a commitment to operational excellence, Repligen is poised for sustainable growth in an industry that is expected to expand significantly over the coming years. For those seeking exposure to the booming biopharmaceutical sector, Repligen offers a unique position that balances innovation, growth potential, and strategic leadership.

RGEN Intrinsic Value
70.02 USD
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Repligen Corp's Other Assets?
Other Assets
985.6m USD

Based on the financial report for Jun 30, 2024, Repligen Corp's Other Assets amounts to 985.6m USD.

What is Repligen Corp's Other Assets growth rate?
Other Assets CAGR 10Y
53%

Over the last year, the Other Assets growth was 13%. The average annual Other Assets growth rates for Repligen Corp have been 17% over the past three years , 16% over the past five years , and 53% over the past ten years .

Back to Top